Last reviewed · How we verify
NCT06213051: HPV
Comparison of Self-collection Using Dry Compared to Wet Swabs for HPV Detection
trial testing • COPAN Self-collection FLOQSwabs® (COPAN, Italy) in Human Papillomavirus Infection in 1,306 participants. Status unknown.
30 September 2024
Quick facts
| Lead sponsor | Foundation for Innovative New Diagnostics, Switzerland |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1,306 |
| Start date | 25 July 2024 |
| Primary completion | 30 September 2024 |
| Estimated completion | 30 September 2024 |
Drugs / interventions tested
- • COPAN Self-collection FLOQSwabs® (COPAN, Italy)
Conditions studied
- Human Papillomavirus Infection — all drugs for Human Papillomavirus Infection →
Sponsor
Foundation for Innovative New Diagnostics, Switzerland
Who can join
Adults 30 to 80, female only, with Human Papillomavirus Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will compare the performance of self-collected vaginal swabs, transported without liquid media (dry swabs) and self-collected vaginal swabs, transported in liquid media (wet swabs) for detection of hrHPV DNA LBC as the reference standard.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06213051
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Human Papillomavirus Infection
Currently open trials in the same condition.
- NCT07281430 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04) · NA · recruiting
- NCT06598475 — Investigating Facilitator-driven, Multi-level Implementation Strategies in Federally Qualified Health Centers to Improve · NA · recruiting
- NCT06611553 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S02) · NA · active not recruiting
- NCT06611540 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03) · NA · active not recruiting
- NCT06498661 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01) · NA · recruiting
Other Foundation for Innovative New Diagnostics, Switzerland trials
Trials by the same sponsor.
- NCT05944731 — Use of Continuous Glucose Monitoring Devices Among People Living With Type 1 Diabetes in Kenya. · NA · unknown
- NCT06118749 — Leishmania Antigen Rapid Diagnostic Test Proof-of-Concept and Validation Study · terminated
- NCT05944718 — Use of Continuous Glucose Monitoring Devices Among People Living With Type 1 Diabetes in South Africa · NA · completed
- NCT06170515 — BGM and HbA1c POC Device Evaluation · NA · unknown
- NCT06225700 — Clinical Validation of Novel Malaria Diagnostic Tools for POC Point-of-Care Testing · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06213051 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Foundation for Innovative New Diagnostics, Switzerland
- Last refreshed: 29 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06213051.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing